Skip to search formSkip to main contentSkip to account menu

MGAH22

Known as: MGAH-22 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Margetuximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.
3004 Background: The anti-HER2 MAb, trastuzumab (H), has proven effective for HER2+ breast cancer (BC) and gastroesophageal… 
2010
2010
Abstract 2581: Development of an Fc-domain-optimized monoclonal antibody with enhanced potency against HER2-expressing tumors
Polymorphic variants of the activating Fcγ receptors (FcγR) expressed in metastatic breast cancer patients predict response… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)